Use of LXR antagonists for treatment of side effects of elevated glucocorticoid levels
AssigneesThe Governing Council of the University of Toronto, Fernando A. Fernandez, Arturo Orellana
InventorsCarolyn Cummins, Arturo Orellana, Rucha Patel, Fernando A. Fernandez
Life of this patent
Estimating the term…
Abstract
The present application is directed to uses of an agent that antagonizes the LXRβ receptor for the treatment of side effects associated with elevated glucocorticoid levels as well as uses of a glucocorticoid in combination with the agent that antagonizes the LXRβ receptor for treatment of a disease wherein glucocorticoid treatment is indicated.
Claims24
A method of treating a side effect of elevated glucocorticoid levels comprising administering a therapeutically effective amount of an agent that antagonizes the LXRβ receptor to a subject in need thereof, wherein the agent that antagonizes the LXRβ receptor is GSK2033, or a pharmaceutically acceptable solvates thereof.
A method of treating a side effect of elevated glucocorticoid levels comprising administering a therapeutically effective amount of an agent that antagonizes the LXRβ receptor to a subject in need thereof, wherein the agent that antagonizes the LXRβ receptor is Amgen54 or a pharmaceutically acceptable solvate thereof.
A method of treating a side effect of elevated glucocorticoid levels comprising administering a therapeutically effective amount of an agent that antagonizes the LXRβ receptor to a subject in need thereof, wherein the agent that antagonizes the LXRβ receptor is DMHCI OR a pharmaceutically acceptable solvate thereof.
Dependencies are inferred from the claim text.